Citations

Clear

16281 citation(s) found for "Yu, David".

Primary Hyperoxaluria (PH) Types 1 and 2 with Kidney and/or Liver Transplant Achieve Best Health-Related Quality of Life (HRQoL)
Milliner, Dawn S. , Modersitzki, Frank , Lieske, John C. , Goldfarb, David S.

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 31 | Issue: 10S | Pages: 176-177

10.1681/asn.20203110s1176c Get It

ILLUMINATE-B, a Phase 3 Open-Label Study to Evaluate Lumasiran, an RNAi Therapeutic, in Young Children with Primary Hyperoxaluria Type 1 (PH1)
Michael, Mini , Cochat, Pierre , Magen, Daniella , Hoff, William van’t , Sas, David J. , Schalk, Gesa, Shasha‐Lavsky, Hadas , Bae, Kyounghwa, Seddighzadeh, Ali, Garg, Pushkal, Vaishnaw, Akshay, McGregor, Tracy L., Fujita, Kenji P. , Frishberg, Yaacov, Deschênes, Georges , Hayes, Wesley Nathan

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 31 | Issue: 10S | Pages: 515-515

10.1681/asn.20203110s1515a Get It

Correspondence on ‘Transradial versus transfemoral access for diagnostic cerebral angiography: frequency of acute MRI findings in 500 consecutive patients at a single center’
Ghozy, Sherief , Brinjikji, Waleed , Cloft, Harry J. , Kallmes, David F. , Ghozy, Sherief

Mayo Clinic

Journal of NeuroInterventional Surgery | May 17, 2024 | Volume: 17 | Issue: 2 | Pages: 229-229

10.1136/jnis-2024-021894 | PMID 38760165 Get It

Semaphorin 3B-Associated Membranous Nephropathy
Sethi, Sanjeev , Charlesworth, M. Cristine , Gross, LouAnn, Buob, David , Tran, Cheryl L. , Emma, Francesco , Dêbiec, Hanna , Madden, Benjamin J. , Vivarelli, Marina , Ravindran, Aishwarya , Diomedi‐Camassei, Francesca , Fervenza, Fernando C. , Ronco, Pierre Marie

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 31 | Issue: 10S | Pages: 25-25

10.1681/asn.20203110s125c Get It

Abstract P199: Oral Microbiome Potentially Modifies the Cardiometabolic Benefits of Nitrate Consumption: Results From the Oral Infections Glucose Intolerance and Insulin Resistance Study (ORIGINS)
Roy, Sumith , Paster, Bruce J. , Chen, Ching-Yuan, Rosenbaum, Michael , Colombo, Paolo , Desvarieux, Moı̈se, Goh, Charlene Enhui , Bohn, Bruno , Genkinger, Jeanine M. , Molinsky, Rebecca , Chen, Ching‐Yuan, Yuzefpolskaya, M. , Knight, Rob , Papapanou, Panos N , Jacobs, David R. , Demmer, Ryan T.

Mayo Clinic

Circulation | May 16, 2024 | Volume: 149 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.149.suppl_1.p199 Get It

Background: Dietary nitrate consumption is associated with cardiometabolic health in many but not all studies. The enterosalivary nitrate-nitrite-nitric oxide (NO 3 - NO 2 - NO) pathway requires the oral microbiome for NO production (a signaling molecule beneficial to cardiometabolic health) following nitrate intake. We hypothesize that the oral microbiome modifies the cardiometabolic benefits of nitrate intake. Methods: We analyzed cross-sectional data from 657 ORGINS participants. Dietary nitrate intakes and alternative healthy eating index (AHEI) scores were calculated from food frequency questionnaire responses and a US food database. Subgingival 16S rRNA microbial genes (Illumina, MiSeq) were sequenced, and PICRUSt2 estimated metagenomic content. The Microbiome Induced Nitric oxide Enrichment Score (MINES) was calculated as a microbial gene abundance ratio representing enhanced net capacity for NO generation. Cardiometabolic biomarker (systolic and diastolic blood pressure, HbA1C, glucose, insulin, and HOMA-IR) Z-scores were averaged to form a cardiometabolic Z-score (CMZ). Adjusted multivariable linear models regressed CMZ and individual Z-scores on nitrate intake tertiles. Results: Participants were mean age 31±9, 72% female, 31% White, 14% Black, and 28% Hispanic. Mean nitrate intake was 189±171 mg/day. Higher nitrate intake was significantly associated with lower CMZ, glucose, insulin, and HOMA-IR. Mean CMZ(SE) across dietary nitrate tertiles were 0.53(0.30), 0.35(0.31), and -0.11(0.30), p for trend=0.04; findings were attenuated after adjustment for AHEI (p for trend=0.12). In subgroup analysis by MINES level, higher nitrate intake was only associated with lower cardiometabolic biomarker levels among participants with a <median MINES even after AHEI adjustment (Table). Conclusion: Higher dietary nitrate intake was associated with lower cardiometabolic risk biomarker levels only among those with reduced potential for oral microbiome-dependent NO generation.
Osteochondroprogenitor cells and neutrophils expressing p21 and senescence markers modulate fracture repair
Saul, Dominik , Doolittle, Madison L. , Froemming, Mitchell N. , Kosinsky, Robyn Laura , Vos, Stephanie J. B. , Ruan, Ming, LeBrasseur, Nathan K. , Chandra, Abhishek , Pignolo, Robert J. , Rowsey, Jennifer L. , Kosinsky, Robyn L, Vos, Stephanie J, LeBrasseur, Nathan K , Kosinsky, Robyn Laura , Saul, Dominik , Chandra, Abhishek , Vos, Stephanie J., Passos, João F. , Farr, Joshua N. , Monroe, David G. , Khosla, Sundeep

Mayo Clinic

Journal of Clinical Investigation | May 16, 2024 | Volume: 134 | Issue: 12 | Pages: No page available

10.1172/jci179834 | PMID 38753433 Get It

Cells expressing features of senescence, including upregulation of p21 and p16, appear transiently following tissue injury, yet the properties of these cells or how they contrast with age-induced senescent cells remains unclear. Here, we used skeletal injury as a model and identified the rapid appearance following fracture of p21 + cells expressing senescence markers, mainly as osteochondroprogenitors (OCHs) and neutrophils. Targeted genetic clearance of p21 + cells suppressed senescence-associated signatures within the fracture callus and accelerated fracture healing. By contrast, p21 + cell clearance did not alter bone loss due to aging; conversely, p16 + cell clearance, known to alleviate skeletal aging, did not affect fracture healing. Following fracture, p21 + neutrophils were enriched in signaling pathways known to induce paracrine stromal senescence, while p21 + OCHs were highly enriched in senescence-associated secretory phenotype factors known to impair bone formation. Further analysis revealed an injury-specific stem cell–like OCH subset that was p21 + and highly inflammatory, with a similar inflammatory mesenchymal population (fibro-adipogenic progenitors) evident following muscle injury. Thus, intercommunicating senescent-like neutrophils and mesenchymal progenitor cells were key regulators of tissue repair in bone and potentially across tissues. Moreover, our findings established contextual roles of p21 + versus p16 + senescent/senescent-like cells that may be leveraged for therapeutic opportunities.
Non–Small Cell Lung Cancer, Version 4.2024
Riely, Gregory J. , Wood, Douglas E. , Ettinger, David S. , Aisner, Dara L. , Akerley, Wallace , Bauman, Jessica R. , Bruno, Débora S. , DeCamp, Malcolm M., Desai, Aakash , Dilling, Thomas J. , Dowell, Jonathan E. , Durm, Gregory A. , Gettinger, Scott , Gubens, Matthew A. , Lackner, Rudy P., Maldonado, Fabien , Morgensztern, Daniel , Mullikin, Trey C. , Ng, Thomas, Owen, Dawn , Patel, Sandip Pravin , Riess, Jonathan W. , Shapiro, Theresa A. , Singh, Aditi P. , Stevenson, James, Tam, Alda L. , Yang, Stephen C. , Yau, Edwin , Gregory, Kristina M., Hang, Lisa, Desai, Aakash P , Bharat, Ankit , Chang, Joe Y. , Chirieac, Lucian R. , Grotz, Travis E. , Juloori, Aditya , Lanuti, Michael D. , Lin, Jules , Loo, Billy W. , Lovly, Christine Marie , Massarelli, Erminia , Owen, Dwight H , Patil, Tejas , Polanco, Patricio Marcelo , Tanvetyanon, Tawee , Yanagawa, Jane

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 16, 2024 | Volume: 22 | Issue: 4 | Pages: 249-274

10.6004/jnccn.2204.0023 | PMID 38754467 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC, including diagnosis, primary disease management, surveillance for relapse, and subsequent treatment. The panel has updated the list of recommended targeted therapies based on recent FDA approvals and clinical data. This selection from the NCCN Guidelines for NSCLC focuses on treatment recommendations for advanced or metastatic NSCLC with actionable molecular biomarkers.
Degenerative mitral regurgitation due to flail leaflet: sex-related differences in presentation, management, and outcomes
Avierinos, Jean-Fançois, Tribouilloy, Christophe , Théron, Alexis , Pradier, J., Benfari, Giovanni , Ruşinaru, Dan, Zaffran, Stéphane , Collart, Frédéric , Théron, Alexis , Biagini, Elena , Barbieri, Andrea , Michelena, Hector, Bohbot, Yohann , Essayagh, Benjamin , Enriquez-Sarano, Maurice , Benfari, Giovanni , Zaffran, Stéphane , Bursi, Francesca , Grigioni, Francesco , Vanoverschelde, Jean‐Louis , Resseguier, Noémie , Pasquet, Agnès , Barbieri, Andréa , Michelena, Héctor I. , Vancraeynest, David , Bohbot, Yohann , Essayagh, Benjamin , Enriquez‐Sarano, Maurice

Mayo Clinic

European Heart Journal | May 16, 2024 | Volume: 45 | Issue: 26 | Pages: 2306-2316

10.1093/eurheartj/ehae265 | PMID 38751052 Get It

Abstract Background and Aims Presentation, outcome, and management of females with degenerative mitral regurgitation (DMR) are undefined. We analysed sex-specific baseline clinical and echocardiographic characteristics at referral for DMR due to flail leaflets and subsequent management and outcomes. Methods In the Mitral Regurgitation International Database (MIDA) international registry, females were compared with males regarding presentation at referral, management, and outcome (survival/heart failure), under medical treatment, post-operatively, and encompassing all follow-up. Results At referral, females (n = 650) vs. males (n = 1660) were older with more severe symptoms and higher MIDA score. Smaller cavity diameters belied higher cardiac dimension indexed to body surface area. Under conservative management, excess mortality vs. expected was observed in males [standardized mortality ratio (SMR) 1.45 (1.27–1.65), P &lt; .001] but was higher in females [SMR 2.00 (1.67–2.38), P &lt; .001]. Female sex was independently associated with mortality [adjusted hazard ratio (HR) 1.29 (1.04–1.61), P = .02], cardiovascular mortality [adjusted HR 1.58 (1.14–2.18), P = .007], and heart failure [adjusted HR 1.36 (1.02–1.81), P = .04] under medical management. Females vs. males were less offered surgical correction (72% vs. 80%, P &lt; .001); however, surgical outcome, adjusted for more severe presentation in females, was similar (P ≥ .09). Ultimately, overall outcome throughout follow-up was worse in females who displayed persistent excess mortality vs. expected [SMR 1.31 (1.16–1.47), P &lt; .001], whereas males enjoyed normal life expectancy restoration [SMR 0.92 (0.85–0.99), P = .036]. Conclusions Females with severe DMR were referred to tertiary centers at a more advanced stage, incurred higher mortality and morbidity under conservative management, and were offered surgery less and later after referral. Ultimately, these sex-related differences yielded persistent excess mortality despite surgery in females with DMR, while males enjoyed restoration of life expectancy, warranting imperative re-evaluation of sex-specific DMR management.
Cross-Sectional Associations of Peripheral Hearing, Brain Imaging, and Cognitive Performance With Speech-in-Noise Performance: The Aging and Cognitive Health Evaluation in Elders Brain Magnetic Resonance Imaging Ancillary Study
Jiang, Kening , Albert, Marilyn , Pankow, James S. , Pike, James Russell , Reed, Nicholas S. , Sharrett, A. Richey, Lin, Frank R. , Study, for the ACHIEVE Collaborative, Sanchez, Victoria A , Deal, Jennifer A , Pankow, James S , Pike, James R , Coresh, Josef , Couper, David , Gottesman, Rebecca F. , Hayden, Kathleen M. , Jack, Clifford R. , Knopman, David S. , Mosley, Thomas H. , Sharrett, A. Richey, Deal, Jennifer A. , Study, for the ACHIEVE Collaborative

Mayo Clinic

American Journal of Audiology | May 15, 2024 | Volume: 33 | Issue: 3 | Pages: 683-694

10.1044/2024_aja-23-00108 | PMID 38748919 Get It

Purpose: Population-based evidence in the interrelationships among hearing, brain structure, and cognition is limited. This study aims to investigate the cross-sectional associations of peripheral hearing, brain imaging measures, and cognitive function with speech-in-noise performance among older adults. Method: We studied 602 participants in the Aging and Cognitive Health Evaluation in Elders (ACHIEVE) brain magnetic resonance imaging (MRI) ancillary study, including 427 ACHIEVE baseline (2018–2020) participants with hearing loss and 175 Atherosclerosis Risk in Communities Neurocognitive Study Visit 6/7 (2016–2017/2018–2019) participants with normal hearing. Speech-in-noise performance, as outcome of interest, was assessed by the Quick Speech-in-Noise (QuickSIN) test (range: 0–30; higher = better). Predictors of interest included (a) peripheral hearing assessed by pure-tone audiometry; (b) brain imaging measures: structural MRI measures, white matter hyperintensities, and diffusion tensor imaging measures; and (c) cognitive performance assessed by a battery of 10 cognitive tests. All predictors were standardized to z scores. We estimated the differences in QuickSIN associated with every standard deviation ( SD ) worse in each predictor (peripheral hearing, brain imaging, and cognition) using multivariable-adjusted linear regression, adjusting for demographic variables, lifestyle, and disease factors (Model 1), and, additionally, for other predictors to assess independent associations (Model 2). Results: Participants were aged 70–84 years, 56% female, and 17% Black. Every SD worse in better-ear 4-frequency pure-tone average was associated with worse QuickSIN (−4.89, 95% confidence interval, CI [−5.57, −4.21]) when participants had peripheral hearing loss, independent of other predictors. Smaller temporal lobe volume was associated with worse QuickSIN, but the association was not independent of other predictors (−0.30, 95% CI [−0.86, 0.26]). Every SD worse in global cognitive performance was independently associated with worse QuickSIN (−0.90, 95% CI [−1.30, −0.50]). Conclusions: Peripheral hearing and cognitive performance are independently associated with speech-in-noise performance among dementia-free older adults. The ongoing ACHIEVE trial will elucidate the effect of a hearing intervention that includes amplification and auditory rehabilitation on speech-in-noise understanding in older adults. Supplemental Material: https://doi.org/10.23641/asha.25733679
Palliative Care for Patients With Cancer: ASCO Guideline Update
Sanders, Justin J. , Temin, Sarah , Ghoshal, Arunangshu , Alesi, Erin R. , Ali, Zipporah , Chauhan, Cynthia, Cleary, James F. , Firn, Janice , Jones, J , Litzow, Mark R. , Lundquist, Debra , Mardones, Mabel Alejandra, Rabow, Michael W. , Rosa, William E. , Ghoshal, Arun , Ali, Zipporah Vunoro , Epstein, Andrew S , Jones, Joshua A , Litzow, Mark R. , Lundquist, Debra , Nipp, Ryan , Rosa, William E , Zimmermann, Camilla , FERRELL, BETTY ROLLING , Nipp, Ryan David

Mayo Clinic

Journal of Clinical Oncology | May 15, 2024 | Volume: 42 | Issue: 19 | Pages: 2336-2357

10.1200/jco.24.00542 | PMID 38748941 Get It

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by providers and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases, or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and 2 (online only) for more. PURPOSE To provide evidence-based guidance to oncology clinicians, patients, nonprofessional caregivers, and palliative care clinicians to update the 2016 ASCO guideline on the integration of palliative care into standard oncology for all patients diagnosed with cancer. METHODS ASCO convened an Expert Panel of medical, radiation, hematology-oncology, oncology nursing, palliative care, social work, ethics, advocacy, and psycho-oncology experts. The Panel conducted a literature search, including systematic reviews, meta-analyses, and randomized controlled trials published from 2015-2023. Outcomes of interest included quality of life (QOL), patient satisfaction, physical and psychological symptoms, survival, and caregiver burden. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS The literature search identified 52 relevant studies to inform the evidence base for this guideline. RECOMMENDATIONS Evidence-based recommendations address the integration of palliative care in oncology. Oncology clinicians should refer patients with advanced solid tumors and hematologic malignancies to specialized interdisciplinary palliative care teams that provide outpatient and inpatient care beginning early in the course of the disease, alongside active treatment of their cancer. For patients with cancer with unaddressed physical, psychosocial, or spiritual distress, cancer care programs should provide dedicated specialist palliative care services complementing existing or emerging supportive care interventions. Oncology clinicians from across the interdisciplinary cancer care team may refer the caregivers (eg, family, chosen family, and friends) of patients with cancer to palliative care teams for additional support. The Expert Panel suggests early palliative care involvement, especially for patients with uncontrolled symptoms and QOL concerns. Clinicians caring for patients with solid tumors on phase I cancer trials may also refer them to specialist palliative care. Additional information is available at www.asco.org/supportive-care-guidelines .